Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
CA 2490714 A1 · Owner: Imtm Gmbh · Inventors: Lendeckel, Uwe; Ansorge, Siegfried; Tadje, Janine
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the use of one or several alanyl-aminopeptidase inhibitors and/or enzyme inhibitors which exhibit the same substrate specificity in order to stimulate the production of TFG-.beta. 1 and the expression of TFG-.beta. 1 in and/or on lymphocyte T regulators. The invention also relates to the use of said inhibitors for preventing and/or curing autoimmune, allergic and cardiovascular diseases and to preclude the rejection of transplants. In addition, said invention relates to applications in which peptidic fragments of pathogenic autoantigens or synthetic analogues and/or specific antigenic components of pathogenic microorganisms are used.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 4, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 4, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 4, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.